|Articles|August 1, 2017

Allergy and anaphylaxis emergency plan form

The American Academy of Pediatrics form for an allergy and anaphylaxis emergency plan.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Teen sports supplements: What to recommend, use with caution, and avoid

Teen sports supplements: What to recommend, use with caution, and avoid

ByColleen Sloan, PA-C, RDN

September 14th 2026

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial | Image Credit: © Yurii Kibalnik - stock.adobe.com

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

ByMorgan Ebert, Executive Editor

September 14th 2026

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

ByMorgan Ebert, Executive Editor

September 14th 2026

FDA approves leniolisib for children aged 4 to 11 with APDS

ByBenjamin P. Saylor

September 11th 2026

FAQ: What's new in COVID-19, RSV, and flu guidance? | Image Credit: © AntonioDiaz - stock.adobe.com

FAQ: What's new in COVID-19, RSV, and flu guidance?

ByContemporary Pediatrics Staff

September 11th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

FAQ: What's new in COVID-19, RSV, and flu guidance?

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

Teen sports supplements: What to recommend, use with caution, and avoid

FDA approves leniolisib for children aged 4 to 11 with APDS

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy